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ORAL CHRONIC GVHD IN CHILDREN—TREATMENT WITH TOPICAL
TACROLIMUS OINTMENT
Albert, M.H., Klein, B., Schuster, F., Binder, V., Nienhoff, C.,
Fu¨hrer, M., Borkhardt, A. Dr. von Haunersches Children’s Hospital,
Pediatric Hematology/Oncology, Munich, Germany.
Oral chronic graft versus host disease (GVHD) frequently pre-
sents as lichen-type changes, hyperkeratotic plaques, pseudomem-
branes, or decreased oral range of motion in patients with sclerotic
features of skin GVHD and is often associated with signiﬁcant
limitations of oral food intake and a generally decreased quality of
life. Decreased oral intake is especially problematic in children
with already reduced caloric uptake due to chronic gastrointestinal
GVHD. Systemic tacrolimus is well established and efﬁcacious for
prophylaxis and treatment of acute and chronic GVHD and topical
tacrolimus has shown activity in chronic GVHD skin lesions. We
therefore initiated a pilot study to investigate the safety and efﬁcacy
of topical tacrolimus ointment in pediatric stem cell transplant
recipients with debilitating oral chronic GVHD. Two patients (6
and 13 years) with -thalassemia were included in the study at 179
and 382 days post transplant respectively. Both suffered from
progressive onset, moderate to severe chronic GVHD with in-
volvement of the oral mucosa exhibiting lichen-type changes
alongside pain, erythema and small ulcerations of the oral mucosa.
One patient additionally presented with progressive sclerosis of the
lips limiting opening of the oral cavity. In both patients oral lesions
had been refractory to systemic GVHD treatment (cyclosporine 3
and 2 mg/kg respectively). After exclusion of infectious causes for
oral lesions, tacrolimus ointment 0.1% (Protopic, Fujisawa
Healthcare) was applied twice daily using a sterile gauze that was
inserted into both buccal pouches and left in place for 20 minutes
without rinsing the mouth afterwards. At a follow up of 24 and 14
weeks respectively, the only side effect observed was a slight burn-
ing discomfort after the ﬁrst application in one patient. Tacrolimus
was absorbed in both patients as exhibited by tacrolimus plasma
levels up to 4.2 and 5.6 ng/ml respectively. Pain, erythematous
lesions and ulcerations disappeared within 4 weeks of treatment in
both. Lichenoid changes markedly improved in both and range of
oral opening normalized in the patient affected. Systemic immu-
nosuppression was tapered during treatment with topical tacroli-
mus in both patients. We conclude that topical application of
tacrolimus ointment holds promise as a safe and efﬁcacious treat-
ment for oral chronic GVHD in children. These ﬁndings deserve
to be afﬁrmed in a larger prospective evaluation.
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TREATING DONOR MICE WITH PALIFERMIN PROTECTS AGAINST THE
DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN A PAREN-
TAL STRAIN3F1-HYBRID MODEL
Ellison, C.A.1,2, Fischer, J.M.M.1, Madkar, B.3, Gartner, J.G.1,4 1.
Department of Pathology, University of Manitoba, Winnipeg, MB,
Canada; 2. Manitoba Blood and Marrow Transplant Program, Cancer-
Care Manitoba, Winnipeg, MB, Canada; 3. BSc. (Medicine) Program,
University of Manitoba, Winnipeg, MB, Canada; 4. Department of
Immunology, University of Manitoba, Winnipeg, MB, Canada.
Treating recipient mice with palifermin protects against the
development of acute, lethal GVHD in murine models induced
without a conditioning regimen. This is associated not only with a
cytoprotective effect in the recipient mice, but also with a change
in the cytokine proﬁle. Whereas untreated recipients develop a
strong Th1-mediated immune response, our previous work using
the C57BL/63(C57BL/6  DBA/2)F1-hybrid model of acute
GVHD showed that palifermin-treated recipients develop a mixed
Th1/Th2 cytokine proﬁle, with a preponderance of Th2 cytokines.
Others have made similar observations. This ﬁnding suggested that
palifermin might also have potent immunoregulatory effects that
mitigate the development of acute GVHD. To study the immu-
noregulatory effects of palifermin in GVH mice independently of
cytoprotective effects that result from treating the recipients with
palifermin, we induced GVHD in (C57BL/6  DBA/2)F1 mice
using grafts from palifermin-treated, C57BL/6 donors. More than
80% of these recipients survived until at least day 150. When we
compared the percentages of total, non-adherent donor spleen
cells, as well as percentages of donor CD4 and donor CD8 on
days 4, 8 and 15 in recipients of grafts from palifermin-treated
donors and recipients of grafts from untreated donors, the per-
centages were lower in the former group at some of these early
time-points. By day 148, the percentages of total non-adherent
donor cells, donor CD4 and donor CD8 cells reached 39%,
21% and 14%, respectively, indicating that the graft had not been
aborted. The percentages of CD4 and CD8 cells were very
similar in grafts of pooled spleen and lymph node cells harvested
from palifermin-treated donors and from untreated donors. Inter-
estingly, the levels of cytotoxic activity directed against YAC-1 and
BW1100 target cells by splenic effector cells from palifermin-
treated donor mice were 2-fold and 5-fold higher, respectively,
when compared to those seen when splenocytes from untreated
donors were used. These ﬁndings show that the ability of palifer-
min to protect against the development of acute GVHD in this
model may be due, at least in part, to its immunoregulatory effects.
They further suggest that palifermin may exert these effects
through a mechanism that involves the activation of donor NK
and/or NKT cells. Supported by a CIHR Operating Grant to JGG
and CAE. Palifermin was kindly provided by Amgen, Inc.
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ALLOANTIGEN AFFINITY AND CD4 HELP DETERMINE SEVERITY OF
GRAFT-VERSUS-HOST DISEASE MEDIATED BY CD8 DONOR T CELLS
Yu, X.-Z.1, Albert, M.H.2, Anasetti, C.1 1. H. Lee Mofﬁtt Cancer
Center, Tampa, FL; 2. Dr. von Haunersches Children’s Hospital, Mu-
nich, Germany.
TCR afﬁnity dictates T cell selection in the thymus and also has a
high impact on the fate of peripheral T cells. Graft-versus-host disease
(GVHD) is a pathological process initiated by activation of donor T
cells after adoptive transfer into an allogeneic recipient. How TCR
afﬁnity affects the potential of alloreactive T cells to induce GVHD is
unclear. Using alloreactive CD4 and CD8 TCR transgenic (Tg)
T cells, GVHD models are presented that allow for the visualization
of how CD8 alloreactive T cells behave in response to alloantigens
with different TCR afﬁnity in the absence or presence of CD4 help.
In a non-myeloablative transplant model where GVHD lethality is
due to marrow aplasia, alloreactive CD8 TCR Tg T cells induced
signiﬁcantly more severe GVHD in the recipients that express an
intermediate afﬁnity alloantigen than in the recipients that express a
high afﬁnity alloantigen. In a myeloablative transplant model where
GVHD lethality is due to epithelium injury, CD8 TCR Tg cells
were also more pathogenic in the recipients with an intermediate
afﬁnity alloantigen than in those with a high afﬁnity alloantigen. The
presence of alloreactive CD4 TCR Tg cells enhanced the potential
of CD8 TCR Tg cells to cause GVHD in recipients with an
intermediate, but not with a high afﬁnity alloantigen. These ﬁndings
underscore that alloantigen afﬁnity and CD4 help control the fate and
pathogenicity of alloreactive CD8 T cells in vivo.
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GRAFT ENGINEERING USING EX VIVO METHODS TO LIMIT GvHD:
FLUDARABINE TREATMENT GENERATES SUPERIOR GvL EFFECTS IN
ALLOGENEIC BMT
Li, J.-M., Giver, C.R., Waller, E.K. Hematology/Oncology, Winship
Cancer Institute, Emory University, Atlanta, GA.
Background: The development of new strategies to inhibit graft
versus host disease ( GVHD) while preserving graft-versus-leukemia
(GvL) activity of donor lymphocytes remains an important challenge
in the ﬁeld of allogeneic bone marrow transplantation (BMT). Several
methods to treat donor lymphocytes ex vivo prior to infusion using
different immunosuppressive agents—ﬂudarabine, psoralen/UVA
(PUVA), or -irradiation—have been tested in allogeneic mouse
models of BMT. While each method has been shown to limit the
GvHD potential of donor cells, their safety, efﬁcacy and GvL activ-
ities have not been directly compared. Methods: Donor/recipient
pairs included MHC fully mismatched (H2b3H2k, H2k3H2b),
MHC haplo-mismatched (H2b3H2b/k, H2b3H2b/d), and MiHA
mismatched (H2k13H2k2) strain combinations. T-cell depleted BM
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(TCD-BM) was transplanted in combination with untreated, ﬂudara-
bine-treated, 7.5Gy -irradiated, or PUVA-treated splenocytes. GvL
activity was studied by administering a lethal number of H2k T
lymphoma cells (LBRM) or H2b myeloid lymphoma cells (C1498).
Post-transplant survival of recipient groups was determined, and
GvHD and GvL effects were assessed by clinical and pathological
scoring. Hematopoietic chimerism and donor T cell expansion were
analyzed by ﬂow cytometric analysis of peripheral blood samples at
days 30 and 60 post-BMT. In addition, the short-term in vitro survival
of memory and naive donor T cell subsets was monitored after
ﬂudarabine, PUVA, or -irradiation. Results: In vitro survival of all
donor T cell subsets 2 days after -irradiation or PUVA was minimal,
while ﬂudarabine-treated T cells demonstrated preferential survival of
memory T-cells. Allogeneic splenocytes treated with ﬂudarabine,
7.5Gy -irradiation, or PUVA had signiﬁcantly diminished GvHD
activity compared to untreated donor splenocytes, and facilitated en-
graftment of low-dose TCD-BM. Fludarabine-treated splenocytes
(and PUVA-treated, to a lesser extent) retained GvL activity and
contributed more to donor T cell engraftment compared to -irradi-
ated donor splenocytes. The results are consistent with other studies
suggesting that donor memory T-cells contribute to GvL activity but
do not produce GvHD.Conclusions: Among ex vivo methods tested
that inhibited GvHD activity of allogeneic lymphocytes, ex vivo treat-
ment with ﬂudarabine is superior to -irradiation or PUVA, resulting
in better separation of GvHD and GvL activities in murine models of
allogeneic BMT.
180
REVEALING KINETICS OF CYTOKINE INDUCED KILLER CELL TRAFFICK-
ING AND SURVIVAL IN VIVO
Nishimura, R., Baker, J., Beilhack, A., Wieland, C.B., Negrin, R.S.
The Division of Bone and Marrow Transplantation, Department of
Medicine, Stanford University School of Medicine, Stanford, CA.
Cytokine induced killer cells (CIK), which are generated from
splenocytes in mice and PBMC in human by the timed addition of
IFN-, anti-CD3 MAbs and IL-2, express both T cell and NK cell
markers. CIK cells kill tumors through NKG2D mediated cyto-
toxicity and have in vivo activity in several murine models. CIK
cells have been utilized in the clinic after both auto and allo
transplant to treat or possibly reduce the risk of disease recurrence.
Our goal was to explore CIK kinetics in vivo in the absence of
exogenous cytokines. To this end, we transplanted luciferase-la-
beled murine CIK cells to compare the trafﬁcking patterns in
different transplant settings (syngeneic vs allogeneic, and myeloa-
blative vs nonmyeloablative) and identiﬁed the survival time of
CIK cells in each BMT setting by in vivo bioluminescence imaging
(BLI). BLI studies showed that CIK cells were proliferated rapidly
in secondary lymphoid organs such as the spleen, cervical and
mesenteric lymph nodes. This observation was similar to the pat-
tern of fresh splenocyte administration. In contrast, severe acute
GVHD was not observed even in CIK dose escalation studies. CIK
cell derived signals were detected more than 80 days after BMT.
Moreover to clarify which lymphocyte subpopulations mainly pro-
liferate in vivo, we also transplanted CIK cells generated from GFP
positive splenocytes and sequentially analyzed tissue distribution.
We conﬁrmed that GFPCD8NKG2D cells expanded in vivo
in allogeneic BMT models. In contrast, syngeneic CIK cells did
not home to any speciﬁc organs and proliferated much less com-
pared to those of allogeneic CIK cells, but GFP positive cells were
detected for at least 21 days after transplantation. We demon-
strated that the kinetics of CIK cell survival was different among
each BMT setting and CIK cells could survive without the addition
of exogenous cytokines in vivo for prolonged periods, especially in
allogeneic BMT settings.
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IMPACT OF ALLOGENEIC SIBLING DONOR-DERIVED PRE-TRANSPLAN-
TATION CD16/56CD3 CELLS
Kim, H.-J.1, Choi, Y.1, Jeong, H.-Y.1, Min, W.-S.1, Kim, S.-Y.1,
Eom, K.-S.1, Lee, S.1, Min, C.-K.1, Cho, S.-G.1, Lee, J.-W.1,
Kim, C.-C.1, Kim, T.-G.2 1. Catholic HSCT Center, St Mary’s Hos-
pital, Catholic Univ of Korea College of Medicine, Seoul, Republic of
Korea; 2. Dept of Microbiology, Catholic Univ of Korea College of
Medicine, Seoul, Republic of Korea.
The associations between the numbers of donor-derived pre-
transplantation CD16/56CD3 cells and clinical outcome were
investigated. Blood samples were obtained from 41 adult HLA-
matched sibling donors on the day of transplantation. The median
percentage of CD16/56 cells recovered from the total MNCs of
the donors was 8.5% (range, 0.9–27%). In addition, the median
percentage of CD16/56CD3 cells from these populations was
3.2% (range, 0.1–10.6%). Patients who received high levels of
donor CD16/56CD3 cells showed more favorable outcomes.
The numbers of donor CD16/56CD3 cells were associated
with the development of acute GVHD (P  .028) and chronic
GVHD (P .0318), suggest a trend towards an inverse correlation
between the numbers of CD16/56CD3 cells and the incidence
of GVHD. The numbers of donor CD16/56CD3 cells in
association with the disease-free survival were not statistically sig-
niﬁcant (P  .0943). However, the higher numbers of donor
CD16/56CD3 cells infused showed signiﬁcantly lower rates of
transplant-related complications (TRC) (P  .02). These results
suggest that the levels of donor CD16/56CD3 cells may be an
evaluable parameter to consider when performing allogeneic he-
matopoietic stem cell transplantation in terms of limiting the
chances of TRC, including GVHD or relapse.
182
SELECTIVE DOWNREGULATION OF ALLOREACTIVITY IN A HUMAN
MODEL OF EXTRACORPOREAL PHOTOTHERAPY TREATMENT OF
GRAFT-VERSUS-HOST DISEASE
Marshall, S.R., Wang, X.N., Dickinson, A.M. Haematological Sciences,
University of Newcastle Upon Tyne, Newcastle Upon Tyne, Tyne &
Wear, United Kingdom.
Graft-versus-host disease (GvHD) remains the most serious
complication following haemopoietic stem cell transplantation,
with an incidence of 40-60% and can be fatal in up to 50% of cases.
Extracorporeal phototherapy (ECP) is a novel treatment of both
acute and chronic GvHD involving psoralen and UVA (PUVA)
treatment of peripheral blood cells with high reported success even
in those resistant to conventional immunosuppressive treatments.
ECP appears to induce selective immune suppression without
increased rates of infection or disease relapse, but its mechanism of
action remains poorly understood. In our department the human
skin explant model for GvHD has been shown to be highly pre-
dictive of clinical GvHD and has been used to investigate the
pathophysiology of the disease. The model involves sensitizing
donor lymphocytes with recipient lymphocytes in vitro in a pri-
mary mixed lymphocyte reaction and then evaluating the second-
ary response on recipient skin biopsies by grading the graft versus
host reactivity (grades I–IV) histopathologically using the Lerner
grading system for GvHD. ECP only treats a small proportion of
circulating mononuclear cells at each visit, but is able to down-
regulate GvHD through effects on untreated cells. Similarly in the
skin explant model, Graft-versus-host reactivity of untreated cells
was inhibited in 11 out of 19 (P  .007) experiments by combining
the untreated cells with PUVA treated cells. Investigation of the
mechanism of this downregulation of alloreactivity revealed inhi-
bition of T cell proliferation with a dose response dependent upon
the ratio of PUVA treated cells to untreated cells. Furthermore
downregulation of T cell proliferation only occurred when PUVA
treatment was performed on sensitized responder cells. Treatment
of naive cells caused minimal or no inhibition. This selective
downregulation of an alloresponse has previously been shown in
mice, but this is the ﬁrst demonstration of the selective action in a
human system. Initial experiments have also shown that combining
PUVA treated and untreated sensitized cells results in downregu-
lation of cell-mediated cytotoxicity. This unique human model of
ECP will allow investigation of cell-mediated and soluble factor
changes associated with PUVA treatment of mononuclear cells and
thus enable us to better understand the mechanism of action of
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